En Bloc Resection of Bladder Tumor—Is It the Way Forward?

Fankhauser, Christian Daniel; Wettstein, Marian S.; Afferi, Luca; Grossmann, Nico C.; Mostafid, Hugh

doi:10.3389/fsurg.2021.685506

Cited by 3 publications

(1 citation statement)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…2 Transurethral resection of bladder tumor (TURBT) is considered the mainstay of treatment for NMIBC and is performed with the goal of complete tumor removal. 3 However, there is a high risk of tumor recurrence and progression in the bladder after TURBT. 4 Hence, intravesical instillation therapy is often used to minimize this risk by delivering medications directly to the bladder to target the remaining cancer cells and prevent their growth.…”

Section: Introductionmentioning

confidence: 99%

Encapsulation of hydroxycamptothecin within porous and hollow poly(l-lactide-co-ε-caprolactone) microspheres as a floating delivery system for intravesical instillation

Zhuang,

Jin,

Cen

et al. 2024

Biomater. Sci.

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

Encapsulation of hydroxycamptothecin within porous and hollow poly(l-lactide-co-ε-caprolactone) microspheres as a floating delivery system for intravesical instillation

Zhuang,

Jin,

Cen

et al. 2024

Biomater. Sci.

View full text Add to dashboard Cite

show abstract

Current opinions regarding the clinical utility of en bloc resection in the treatment of non-muscle invasive bladder cancer—a review of the literature

Gao

2024

Discov Onc

View full text Add to dashboard Cite

Non-muscle invasive bladder cancer (NMIBC) is currently mainly treated with the approach of transurethral resection of bladder tumor (TURBT) followed by pathology investigation of the obtained specimens. However, this approach—TURBT—has a few drawbacks, owing to the inherent technical defect—“piecemeal” resection. With development of medical science and surgical techniques, a new kind of surgical operation—“en bloc” resection of bladder tumor (ERBT)—emerged, hoping to completely remove bladder tumor with surrounding normal tissue. The detrusor muscle layer beneath the tumor is removed, and the surgical quality of bladder tumor is enhanced, with a better pathological outcome, reduced intraoperative complications and lower recurrence rate eventually. This paper reviews current literature concerning a brief history of ERBT developing, surgical steps, its indications, advantages on surgical margin, recurrence during follow-up, pathological performance—presence of detrusor muscle, residual tumor and upstage, as well as such issue as “is reTURBT necessary after ERBT?” and the guiding significance of ERBT in substaging of T1 bladder cancer.

show abstract

Comparison of en-bloc resection of the bladder wall and tumor with standard transurethral bladder resection in treatment of non-muscle invasive bladder cancer

Kotov,

Guspanov,

Pulbere

et al. 2024

Onkourologiâ

View full text Add to dashboard Cite

Background. Bladder cancer currently poses a major challenge to urologic oncologists worldwide due to its high recurrence rates. Although the treatment of non-muscle invasive bladder cancer does not carry the same risks as the treatment of muscle invasive forms, frequent recurrences and subsequent tumor progression can lead to patients undergoing disabling organ-removing operations with great risk to life and health. Therefore, improvement of treatment methods for non-muscle invasive bladder cancer may make the quality of life of patients with these diseases better.Aim. To evaluate the safety and effectiveness of en-bloc transurethral resection of bladder tumor (eTURBT) compared with conventional TURBT (cTURBT) in the treatment of patients with non-muscle invasive bladder cancer.Materials and methods. The retrospective study included 197 patients with newly diagnosed primary non-muscle invasive bladder cancer who underwent eTURBT (n = 34) or cTURBT (n = 163) at the University Urology Clinic between 2011 and 2021. The groups did not have statistically significant differences in gender, age, and tumor characteristics. Median follow-up was 28.25 months.Results. Both groups had comparable perioperative indicators, but the quality of the material obtained after eTURBT was better than after cTURBT. Patients with adjuvant intravesical chemotherapy in the early postoperative period had better oncological results compared with patients without it (35.71 % recurrences and/or progression versus 49.12 %) (p <0.05). Additionally, in the eTURBT group the number of recurrences was significantly lower: 14.71 % versus 40.49 % (p <0.05).Conclusion. In the absence of contraindications for eTURBT, this method of surgical treatment of non-muscle invasive bladder cancer with adjuvant intravesical chemotherapy in the early postoperative period seems more promising with better oncological indicators.

show abstract

En Bloc Resection of Bladder Tumor—Is It the Way Forward?

Cited by 3 publications

References 20 publications

Encapsulation of hydroxycamptothecin within porous and hollow poly(l-lactide-co-ε-caprolactone) microspheres as a floating delivery system for intravesical instillation

Encapsulation of hydroxycamptothecin within porous and hollow poly(l-lactide-co-ε-caprolactone) microspheres as a floating delivery system for intravesical instillation

Current opinions regarding the clinical utility of en bloc resection in the treatment of non-muscle invasive bladder cancer—a review of the literature

Comparison of en-bloc resection of the bladder wall and tumor with standard transurethral bladder resection in treatment of non-muscle invasive bladder cancer

Contact Info

Product

Resources

About